DOCKET NO.: FCCC-0004 (99-01; WO/386)

Application No.: 09/868,196

Office Action Dated: September 10, 2003

This listing of claims will replace all prior versions, and listings, of claims in the application.

PATENT

Listing of Claims:

1-44. Canceled

45. (Currently amended) A method of treating or preventing <u>clinically manifest</u> mammary tumors, comprising administering a host <u>having a clinically manifest mammary tumor</u> in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor

cells.

46-54. Canceled

55. (Currently amended) The method of claim 45 [[54]], wherein the elinically

manifest mammary tumor is a primary tumor.

56. (Currently amended) The method of claim 55 [[45]], wherein the mammary

tumor is a non-invasive carcinoma.

57. (Previously presented) The method of claim 56, wherein the carcinoma is ductal

carcinoma in situ or lobular carcinoma in situ.

58. (Previously presented) The method of claim 45, wherein the mammary tumor is

an invasive carcinoma.

59. (Previously presented) The method of claim 58, wherein the carcinoma is tubular

or lobular invasive carcinoma.

60. (Currently amended) The method of claim 45 [[54]], wherein the elinically

manifest mammary tumor is a metastatic mammary tumor.

Page 2 of 12

DOCKET NO.: FCCC-0004 (99-01; WO/386) **PATENT**

Application No.: 09/868,196

Office Action Dated: September 10, 2003

61. (Previously presented) The method of claim 45, wherein the host is a premenopausal woman.

62. (Previously presented) The method of claim 45, wherein the host is a postmenopausal woman.

63. (Previously presented) The method of claim 45, combined with at least one other cancer therapy.

64. (Previously presented) The method of claim 63, wherein the at least one other cancer therapy is surgery or chemotherapy.

65. (Previously presented) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66-69. Canceled

70. (Previously presented) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

71. (Previously presented) The method of claim 45, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

72. (Previously presented) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

73. (Previously presented) The method of claim 45, wherein the hCG is administered every second day.

74. (Previously presented) The method of claim 45, wherein the hCG is administered three times each week.

DOCKET NO.: FCCC-0004 (99-01; WO/386)

Application No.: 09/868,196

Office Action Dated: September 10, 2003

75. (Previously presented) The method of claim 45, wherein the hCG is administered for several weeks.

PATENT

76. (Previously presented) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

77. (Previously presented) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (Previously presented) The method of claim 45, wherein the hCG is administered in combination with Type 1 interferon.

79. Canceled.

80. (Previously presented) The method of claim 45, wherein the hCG is recombinant hCG.

81-103. Canceled